(6-265) Cost-Effectiveness Analysis of Enfortumab Vedotin and Pembrolizumab vs. Nivolumab with Chemotherapy or Standard of Care Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Tuesday, December 10, 2024
10:45 AM – 11:45 AM
Location: Hall G, Lower Level
Category: Evaluative Study Topic: Oncology/Hematology
Co-Author(s): Atreya Ghosh, Christian A. Fernandez, Kangho Suh
